{"name": "Zafgen",
 "permalink": "zafgen",
 "crunchbase_url": "http://www.crunchbase.com/company/zafgen",
 "homepage_url": "http://www.zafgen.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2005,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@zafgen.com",
 "phone_number": "617-864-1645",
 "description": "",
 "created_at": "Sat Mar 13 03:12:27 UTC 2010",
 "updated_at": "Wed Dec 05 10:49:07 UTC 2012",
 "overview": "\u003Cp\u003EZafgen is the world\u00e2\u20ac\u2122s first biopharmaceutical company dedicated to developing novel obesity therapeutics that directly target and shrink fat tissue to help the body regain and sustain a lean, healthy state. Adipose tissue (fat) is composed primarily of cells that store unused calories for later use. The balance between how the body stores excess calories and later accesses these depots when required plays a critical role in determining the overall size of the fat tissue, and therefore, an individual\u0026#8217;s weight. Zafgen\u00e2\u20ac\u2122s groundbreaking approach targets obesity at its biological foundation by safely restoring the balance of fat metabolism, driving the loss of fat and a return to a more healthy body weight. Zafgen\u00e2\u20ac\u2122s leadership and scientific advisors include the leading experts in obesity, metabolic disorders and medicinal chemistry. Founded in 2005, the company is located in Cambridge, Massachusetts.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       56],
      "assets/images/resized/0008/0171/80171v1-max-150x150.jpg"],
     [[250,
       93],
      "assets/images/resized/0008/0171/80171v1-max-250x250.jpg"],
     [[321,
       120],
      "assets/images/resized/0008/0171/80171v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Thomas",
      "last_name": "E. Hughes",
      "permalink": "thomas-e-hughes",
      "image":
       {"available_sizes":
         [[[125,
            150],
           "assets/images/resized/0022/3943/223943v1-max-150x150.jpg"],
          [[134,
            160],
           "assets/images/resized/0022/3943/223943v1-max-250x250.jpg"],
          [[134,
            160],
           "assets/images/resized/0022/3943/223943v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Chief Medical Officer",
    "person":
     {"first_name": "Dennis",
      "last_name": "D. Kim",
      "permalink": "dennis-d-kim",
      "image":
       {"available_sizes":
         [[[125,
            150],
           "assets/images/resized/0022/3944/223944v1-max-150x150.jpg"],
          [[134,
            160],
           "assets/images/resized/0022/3944/223944v1-max-250x250.jpg"],
          [[134,
            160],
           "assets/images/resized/0022/3944/223944v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Chief Financial Officer and Vice President of Business Development",
    "person":
     {"first_name": "Matthias",
      "last_name": "B. Jaffe",
      "permalink": "matthias-b-jaffe",
      "image":
       {"available_sizes":
         [[[125,
            150],
           "assets/images/resized/0022/3945/223945v1-max-150x150.jpg"],
          [[134,
            160],
           "assets/images/resized/0022/3945/223945v1-max-250x250.jpg"],
          [[134,
            160],
           "assets/images/resized/0022/3945/223945v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board Member",
    "person":
     {"first_name": "Kevin",
      "last_name": "Starr",
      "permalink": "kevin-starr",
      "image": null}},
   {"is_past": true,
    "title": "Interin CEO",
    "person":
     {"first_name": "Kevin",
      "last_name": "Starr",
      "permalink": "kevin-starr",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$90.2M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://onbiovc.com/zafgen-inc-series-b-81m/",
    "source_description": "ZafGen, Inc.: Series B $8.1M",
    "raised_amount": 28000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 3,
    "funded_day": 29,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Atlas Venture",
         "permalink": "atlas-venture",
         "image":
          {"available_sizes":
            [[[150,
               31],
              "assets/images/resized/0000/3403/3403v2-max-150x150.png"],
             [[250,
               53],
              "assets/images/resized/0000/3403/3403v2-max-250x250.png"],
             [[297,
               63],
              "assets/images/resized/0000/3403/3403v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Third Rock Ventures",
         "permalink": "third-rock-ventures-2",
         "image":
          {"available_sizes":
            [[[150,
               78],
              "assets/images/resized/0005/0700/50700v1-max-150x150.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-250x250.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "GreatPoint Ventures",
         "permalink": "greatpoint-ventures",
         "image":
          {"available_sizes":
            [[[150,
               72],
              "assets/images/resized/0005/1952/51952v1-max-150x150.jpg"],
             [[165,
               80],
              "assets/images/resized/0005/1952/51952v1-max-250x250.jpg"],
             [[165,
               80],
              "assets/images/resized/0005/1952/51952v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "a",
    "source_url": "",
    "source_description": "EDGAR",
    "raised_amount": 5180000.0,
    "raised_currency_code": "USD",
    "funded_year": 2006,
    "funded_month": 9,
    "funded_day": 11,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Atlas Venture",
         "permalink": "atlas-venture",
         "image":
          {"available_sizes":
            [[[150,
               31],
              "assets/images/resized/0000/3403/3403v2-max-150x150.png"],
             [[250,
               53],
              "assets/images/resized/0000/3403/3403v2-max-250x250.png"],
             [[297,
               63],
              "assets/images/resized/0000/3403/3403v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "GreatPoint Ventures",
         "permalink": "greatpoint-ventures",
         "image":
          {"available_sizes":
            [[[150,
               72],
              "assets/images/resized/0005/1952/51952v1-max-150x150.jpg"],
             [[165,
               80],
              "assets/images/resized/0005/1952/51952v1-max-250x250.jpg"],
             [[165,
               80],
              "assets/images/resized/0005/1952/51952v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "c",
    "source_url": "http://eon.businesswire.com/news/eon/20110707005275/en/Series-C-Financing/Obesity-drug/bariatric-surgery",
    "source_description": "Zafgen Secures $33 Million Series C Financing",
    "raised_amount": 33000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 7,
    "funded_day": 7,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Atlas Venture",
         "permalink": "atlas-venture",
         "image":
          {"available_sizes":
            [[[150,
               31],
              "assets/images/resized/0000/3403/3403v2-max-150x150.png"],
             [[250,
               53],
              "assets/images/resized/0000/3403/3403v2-max-250x250.png"],
             [[297,
               63],
              "assets/images/resized/0000/3403/3403v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Third Rock Ventures",
         "permalink": "third-rock-ventures-2",
         "image":
          {"available_sizes":
            [[[150,
               78],
              "assets/images/resized/0005/0700/50700v1-max-150x150.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-250x250.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "debt_round",
    "source_url": "http://www.masshightech.com/stories/2012/08/27/daily22-Zafgen-raises-3M-for-weight-loss-drug.html",
    "source_description": "Zafgen raises $3M for weight-loss drug",
    "raised_amount": 3000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 8,
    "funded_day": 28,
    "investments":
     []},
   {"round_code": "d",
    "source_url": "http://www.masshightech.com/stories/2012/12/03/daily18-Obesity-drug-developer-Zafgen-raises-21M.html",
    "source_description": "Obesity drug developer Zafgen raises $21M",
    "raised_amount": 21000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 12,
    "funded_day": 4,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Alta Partners",
         "permalink": "alta-partners",
         "image":
          {"available_sizes":
            [[[150,
               22],
              "assets/images/resized/0003/4978/34978v1-max-150x150.png"],
             [[168,
               25],
              "assets/images/resized/0003/4978/34978v1-max-250x250.png"],
             [[168,
               25],
              "assets/images/resized/0003/4978/34978v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Atlas Venture",
         "permalink": "atlas-venture",
         "image":
          {"available_sizes":
            [[[150,
               31],
              "assets/images/resized/0000/3403/3403v2-max-150x150.png"],
             [[250,
               53],
              "assets/images/resized/0000/3403/3403v2-max-250x250.png"],
             [[297,
               63],
              "assets/images/resized/0000/3403/3403v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Third Rock Ventures",
         "permalink": "third-rock-ventures-2",
         "image":
          {"available_sizes":
            [[[150,
               78],
              "assets/images/resized/0005/0700/50700v1-max-150x150.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-250x250.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "5 Cambridge Center, Floor 2",
    "address2": "",
    "zip_code": "02142",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "obesity drug showing promise",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 5,
    "source_url": "http://www.masshightech.com/stories/2011/01/03/daily40-Zafgens-obesity-drug-shows-promise-in-early-study.html",
    "source_text": null,
    "source_description": "Zafgen's obesity drug shows promise in early study",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Zafgen",
      "permalink": "zafgen"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        109],
       "assets/images/resized/0008/0172/80172v1-max-150x150.jpg"],
      [[250,
        182],
       "assets/images/resized/0008/0172/80172v1-max-250x250.jpg"],
      [[450,
        328],
       "assets/images/resized/0008/0172/80172v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}